Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine

Deok-Beom Jung^{1

2}, Miyong Yun^{1

2}, Eun-Ok Kim^{1

3}, Jaekwang Kim¹, Bonglee Kim¹, Ji Hoon Jung¹, Enfeng Wang⁴, Debabrata Mukopadhyay⁴, Edward Hammond⁵, Keith Dredge⁵, Viji Shridhar^{6

7}, Sung-Hoon Kim^{1

7}

Affiliations

¹ College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
² These authors contributed equally to this work.
³ Korean Medicine Clinical Trial Center, Kyung Hee University, Seoul, South Korea.
⁴ Department of Biochemistry and Molecular Biology, MN, USA.
⁵ Progen Pharmaceuticals Ltd, Brisbane, Queensland, Australia.
⁶ Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
⁷ These authors are senior authors.

Published Erratum

Deok-Beom Jung et al. Oncotarget. 2019.

. 2019 Sep 24;10(54):5669.

doi: 10.18632/oncotarget.27216.

¹ College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
² These authors contributed equally to this work.
³ Korean Medicine Clinical Trial Center, Kyung Hee University, Seoul, South Korea.
⁴ Department of Biochemistry and Molecular Biology, MN, USA.
⁵ Progen Pharmaceuticals Ltd, Brisbane, Queensland, Australia.
⁶ Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
⁷ These authors are senior authors.